Navigation Links
TGen licenses first drug for patient use in clinical care
Date:5/4/2011

PHOENIX, Ariz. May 4, 2011 The Translational Genomics Research Institute (TGen) has licensed its first drug, a unique compound that targets cancer tumors by modifying the actions of proteins.

Today's announcement is another key fulfillment of TGen's primary mission: To move laboratory discoveries more rapidly into therapeutics that can immediately help patients improve their quality of life.

The drug, ONCO-101, is being licensed to Syracuse, N.Y.-based Oncoholdings Inc., a pharmaceutical company focused on the acquisition and development of innovative anti-cancer compounds.

Oncoholdings, in turn, has contracted with a TGen subsidiary, Scottsdale-based TGen Drug Development (TD2), to help guide continued pre-clinical tests, and eventually move ONCO-101 into first-in-human clinical trials, where it could immediate help cancer patients.

"This milestone is a significant accomplishment that validates the clinical groundwork we established when forming TGen," said Dr. Jeffrey Trent, TGen President and Research Director. "Because ONCO-101 could potentially change the way patients with ovarian and endometrial cancer are treated, we hope this is but the first of many compounds that benefit patients battling life-threatening illnesses."

Licensing ONCO-101 comes nearly nine years after the establishment of TGen, an integral piece of Arizona's bioscience initiative. The goals of that initiative are to: enable scientific discoveries; improve the quality of health care, especially for Arizona residents; and diversifying the state's knowledge-based economy.

ONCO-101 was developed at TGen in the course of research into the design of drugs that selectively target key proteins involved in cancers.

TGen granted Oncoholdings the exclusive license to further develop ONCO-101, an epigenetic agent, or compound, that decides how active proteins become. Currently, there are only four epigenetic drugs on the market, and they are only approved to treat blood cancers. ONCO-101 would be the first epigenetic agent to attack solid tumors.

"This class of therapeutic agents has yet to find its place in the market for the treatment of solid tumors," according to Jeffrey Evans, Ph.D. and Chief Operating Officer of Oncoholdings. "ONCO-101 works by allowing the regular function of normal cells, while disrupting the ability of abnormal cells to reproduce, effectively stopping the cancer."

Oncoholdings expects to announce the acquisition of its second group of products in the second quarter of 2011.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. The Indiana Clinical and Translational Science Institute (CTSI) Licenses GeneGos Eureka and MetaCore Platforms
2. Cells talk more in areas Alzheimers hits first, boosting plaque component
3. Study is the first to link sleep duration to infant growth spurts
4. Cedars-Sinai to hold first annual conference on stem cell therapies for neurological disorders
5. Success of First World Congress of Pediatric Urology underscores increasing importance of specialty
6. Alzheimers diagnostic guidelines updated for first time in decades
7. University of Granada researchers make the first bioartificial organ in Spain
8. First clinical trial of gene therapy for pain reported by U-M neurologists
9. Simple chemical cocktail shows first promise for limb re-growth in mammals
10. John Theurer Cancer Center first in New Jersey to offer complete capabilities of Provenge
11. Study provides first link between 2 major Parkinsons genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
(Date:10/12/2017)... ... 12, 2017 , ... Health Literacy Innovations (HLI), creator of ... and the Cancer Patient Education Network (CPEN), an independent professional organization that shares ... strategic alliance. , As CPEN’s strategic partner, HLI will help support CPEN ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... Sept. 12, 2017  Consumer reviews on the independent review site ... the number one company for hearing aids, ranking it higher than ... brands. ... #1 by Consumers For Hearing Aids ... Hearing is an online store that provides high performance, state-of-the-art, German-engineered ...
Breaking Medicine Technology: